@article{10dbd96bbac54f4eaadb013f73d70b72,
title = "Impact of autologous blood transfusion after bone marrow harvest on unrelated donor{\textquoteright}s health and outcome: a CIBMTR analysis",
abstract = "Pre-harvest autologous blood collection from bone marrow (BM) donors is performed to meet potential post-operative transfusion needs. This study examines the impact of autologous blood transfusion on BM donor{\textquoteright}s health and safety. The study included first-time unrelated BM donors from the United States whose BM harvest was facilitated by the National Marrow Donor Program (NMDP) centers between 2006 and 2017. Examination of 7024 BM donors revealed that 60% received at least one unit of autologous blood. The donors who received autologous blood were older, had lower hemoglobin pre-harvest, underwent longer duration of anesthesia, and higher volume BM harvest. Only donors who underwent high-volume BM harvest, defined as a BM harvest volume >27% of donor{\textquoteright}s blood volume, benefited from autologous transfusion. After a high-volume BM harvest, autologous blood transfusion was shown to decrease grade 2 to 4 collection-associated toxicities within 48 h of BM donation (p = 0.010) and shorten the time to donor-reported “complete” recovery from donation-associated symptoms (p < 0.001). Therefore, autologous transfusion could be avoided as support of marrow donation in the majority of unrelated BM donors and should be limited to cases where the planned BM harvest volume is expected to exceed 27% of donor{\textquoteright}s blood volume.",
author = "Nosha Farhadfar and Murthy, {Hemant S.} and Logan, {Brent R.} and Sees, {Jennifer A.} and Mouhab Ayas and Minoo Battiwalla and Beitinjaneh, {Amer M.} and Saurabh Chhabra and Diaz, {Miguel Angel} and Katie Engles and Haydar Frangoul and Siddhartha Ganguly and Usama Gergis and Kamani, {Nayesh R.} and Kamble, {Rammurti T.} and Kasow, {Kimberly A.} and Lazarus, {Hillard M.} and Liesveld, {Jane L.} and Maxim Norkin and {O{\textquoteright} Donnell}, {Paul V.} and Olsson, {Richard F.} and Susan Rossmann and Savani, {Bipin N.} and Raquel Schears and Sachiko Seo and Solh, {Melhem M.} and Thomas Spitzer and Michele Sugrue and Yared, {Jean A.} and Michael Linenberger and Joseph Schwartz and Pulsipher, {Michael A.} and Shah, {Nirali N.} and Switzer, {Galen E.} and Confer, {Dennis L.} and Shaw, {Bronwen E.} and Wingard, {John R.}",
note = "Funding Information: Acknowledgements The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 1U24HL138660 from NHLBI and NCI; a contract HHSH2502017000 06C with Health Resources and Services Administration (HRSA/ DHHS); three Grants N00014-17-1-2388, N00014-17-1-2850, and N00014-18-1-2045 from the Office of Naval Research; and grants from Adaptive Biotechnologies; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; *Chimerix, Inc.; *CytoSen Therapeutics, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; *Kite Pharma, Inc.; Medac, GmbH; *Mediware; The Medical College of Wisconsin; *Merck & Co, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Pharmaceuticals Corporation; PCORI; *Pfizer, Inc; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals, Inc.; St. Baldrick{\textquoteright}s Foundation; Swedish Orphan Biovitrum, Inc.; *Takeda Oncology; and University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members Author contributions NF, HSM, JRW, and BES designed the study, developed the protocol, interpreted the data, and wrote the manuscript. BRL and JAS designed the study, analyzed and interpreted the data, and generated the figures. AM, MB, AMB, SC, MAD, KE, HF, SG, UG, NRK, RTK, KAK, HML, JLL, MN, PVO, RFO, SNR, BNS, RS, SS, MMS, TS, MS, JAY, ML, JS, MAP, NNS, GES,and DLC participated in the design of the study and edited the final manuscript. The final manuscript was reviewed and approved by all authors. Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to Springer Nature Limited. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = nov,
day = "1",
doi = "10.1038/s41409-020-0911-8",
language = "English (US)",
volume = "55",
pages = "2121--2131",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",
}